Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia

L. Maude, Shannon; W. Laetsch, Theodore; Buechner, Jochen; Rives, Susana; Boyer, Michael; Bittencourt, Henrique; Bader, Peter; R. Verneris, Michael; E. Stefanski, Heather; D. Myers, Gary; Qayed, Muna; De Moerloose, Barbara; Hiramatsu, Hidefumi; Schlis, Krysta; L. Davis, Kara; L. Martin, Paul; R. Nemecek, Eneida; A. Yanik, Gregory; Peters, Christina; Baruchel, André; Boissel, Nicolas; Méchinaud, Françoise; Balduzzi, Adriana; Krueger, Joerg; H. June, Carl; L. Levine, Bruce; A. Wood, Patricia; Taran, Tetiana; Leung, Mimi; T. Mueller, Karen; Zhang, Yiyun; Sen, Kapildeb; Lebwohl, David; A. Pulsipher, Michael; A. Grupp, Stephan

doi:10.1056/nejmoa1709866

Public

Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia

Published in New England Journal of Medicine • Jan 31, 2018

Authors:

Shannon L. Maude

Theodore W. Laetsch

Jochen Buechner

Abstract

BACKGROUND: In a single-center phase 1-2a study, the anti-CD19 chimeric antigen receptor (CAR) T-cell therapy tisagenlecleucel produced high rates of complete remission and was associated with serious but mainly reversible toxic effects in children and young adults with relapsed or refractory B-cell...

Subject

Lymphoblastic Leukemia

Medicine

Leukemia

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!